Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice

Psychopharmacology

Volumn 181, Issue 1, 2005, Pages 71-79

  Lazzarini, M ^a   Salum, C ^a   Del Bel, E A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

7NI; Antioxidant; Catalepsy; Haloperidol; LNAME; LNOARG; Motor behavior; Striatum; Vitamin C; Vitamin E

Indexed keywords

7 NITROINDAZOLE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; MALE; MOUSE; NITRERGIC NERVE; NONHUMAN; PRIORITY JOURNAL; TASK PERFORMANCE;

ALPHA-TOCOPHEROL; ANIMALS; ASCORBIC ACID; CATALEPSY; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG TOLERANCE; ENZYME INHIBITORS; HALOPERIDOL; INDAZOLES; MALE; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROARGININE; TIME FACTORS; VITAMINS;

EID: 26644435797     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2222-6     Document Type: Article

References (81)

1. Abekawa T, Ohmori T, Koyama T (1994) Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res 643:276-281
2. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, Angrist B (1993) Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 150:1405-1407
3. Azzi A, Stocker A (2000) Vitamin E: non-antioxidant roles. Prog Lipid Res 39:231-255
4. Babbedge RC, Bland-Ward PA, Hart SL, Moore PK (1993) Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br J Pharmacol 110:225-228
5. Bacopoulos NG (1982) Dopamine receptors in rat brain regions. Optimal conditions for 3H-agonist binding, pH dependency and lack of inhibition by ascorbic acid. Biochem Pharmacol 31:3085-3091
6. Barak Y, Swartz M, Shamir E, Stein D, Weizman A (1998) Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatry 10:101-105
7. Behl C, Rupprecht R, Skutella T, Holsboer F (1995) Haloperidol-induced cell death - mechanism and protection with vitamin E in vitro. NeuroReport 7:360-364
8. Boscoboinik D, Szewczyk A, Azzi A (1991) Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity. Arch Biochem Biophys 286:264-269
9. Boulay D, Depoortere R, Oblin A, Sanger DJ, Schoemaker H, Perrault G (2000) Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice. Eur J Pharmacol 391:63-73
10. Bowyer JF, Clausing P, Gough B, Slikker W Jr, Holson RR (1995) Nitric oxide regulation of methamphetamine-induced dopamine release in caudate/putamen. Brain Res 699:62-70
11. Brigelius-Flohe R, Traber MG (1999) Vitamin E: function and metabolism. FASEB J 13:1145-1155
12. Bush MA, Pollack GM (2001) Pharmacokinetics and pharmacodynamics of 7-nitroindazole, a selective nitric oxide synthase inhibitor, in the rat hippocampus. Pharm Res 18:1607-1612
13. Cadet JL, Katz M, Jackson-Lewis V, Fahn S (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476:10-15
14. Carr A, Frei B (1999) Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J 13:1007-1024
15. Choi DW (1993) Nitric oxide: foe or friend to the injured brain? Proc Natl Acad Sci U S A 90:9741-9743
16. Cohen G (1994) Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defenses. Ann N Y Acad Sci 738:8-14
17. Coppens HJ, Sebens JB, Korf J (1995) Catalepsy, Fos protein, and dopamine receptor occupancy after long-term haloperidol treatment. Pharmacol Biochem Behav 51:175-182
18. Del Bel EA, Guimarães FS (2000) Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice. Psychopharmacology (Berl) 147:356-361
19. Del Bel EA, da Silva CA, Guimarães FS (1998) Catalepsy induced by nitric oxide synthase inhibitors. Gen Pharmacol 30:245-248
20. Del Bel EA, Souza AS, Guimarães FS, da-Silva CA, Nucci-da-Silva LP (2002) Motor effects of acute and chronic inhibition of nitric oxide synthesis in mice. Psychopharmacology (Berl) 161:32-37
21. Del Bel EA, da Silva CA, Guimarães FS, Bermudez-Echeverry M (2004) Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. Eur J Pharmacol 485:175-181
22. Dexter DT, Nanayakkara I, Goss-Sampson MA, Muller DP, Harding AE, Marsden CD, Jenner P (1994) Nigral dopaminergic cell loss in vitamin E deficient rats. NeuroReport 5:1773-1776
23. Dorevitch A, Kalian M, Shlafman M, Lerner V (1997) Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 41:114-116
24. Dorfman-Etrog P, Hermesh H, Prilipko L, Weizman A, Munitz H (1999) The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study. Eur Neuropsychopharmacol 9:475-477
25. Dorris RL, Dill RE (1986) Potentiation of haloperidol-induced catalepsy by ascorbic acid in rats and nonhuman primates. Pharmacol Biochem Behav 24:781-783
26. Dunlap CE III, Leslie FM (1985) Effect of ascorbate on the toxicity of morphine in mice. Neuropharmacology 24:797-804
27. Ebadi M, Srinivasan SK, Baxi MD (1996) Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 48:1-19
28. Ewing AG, Alloway KD, Curtis SD, Dayton MA, Wightman RM, Rebec GV (1983) Simultaneous electrochemical and unit recording measurements: characterization of the effects of D-amphetamine and ascorbic acid on neostriatal neurons. Brain Res 261:101-108
29. Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32(Suppl):S128-S132
30. Garthwaite J (1991) Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 14:60-67
31. Gotz ME, Kunig G, Riederer P, Youdim MB (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63:37-122
32. Greenblatt EN, Coupet J, Rauh E, Szucs-Myers VA (1980) Is dopamine antagonism a requisite of neuroleptic activity? Arch Int Pharmacodyn Ther 248:105-119
33. Guimarães FS, de Aguiar JC, Del Bel EA, Ballejo G (1994) Anxiolytic effect of nitric oxide synthase inhibitors microinjected into the dorsal central grey. NeuroReport 3:1929-1932
34. Gulley JM, Rebec GV (1999) Modulatory effects of ascorbate, alone or with haloperidol, on a lever-release conditioned avoidance response task. Pharmacol Biochem Behav 63:125-129
35. Heikkila RE, Cabbat FS, Manzino L (1981) Differential inhibitory effects of ascorbic acid on the binding of dopamine agonists and antagonists to neostriatal membrane preparations: correlations with behavioral effects. Res Commun Chem Pathol Pharmacol 34:409-421
36. Heikkila RE, Manzino L, Cabbat FS, Hanly JG (1983) Ascorbic acid and the binding of DA agonists to neostriatal membrane preparations. Neuropharmacology 22:135-137
37. Hoyt KR, Tang LH, Aizenman E, Reynolds IJ (1992) Nitric oxide modulates NMDA-induced increases in intracellular Ca2+ in cultured rat forebrain neurons. Brain Res 592:310-316
38. Kawabata A, Umeda N, Takagi H (1993) L-Arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met- enkephalin pathway and NO-cyclic GMP pathway. Br J Pharmacol 109:73-79
39. Kiyatkin EA, Rebec GV (1998) Ascorbate modulates glutamate-induced excitations of striatal neurons. Brain Res 812:14-22
40. Koffer KB, Berney S, Hornykiewicz O (1978) The role of the corpus striatum in neuroleptic- and narcotic-induced catalepsy. Eur J Pharmacol 47:81-86
41. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS (1993) A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364:626-632
42. Lohr JB, Cadet JL, Lohr MA, Larson L, Wash E, Wade L, Hylton R, Vidoni C, Jeste DV, Wyatt RJ (1988) Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 14:291-296
43. Manzoni O, Bockaert J (1993) Nitric oxide synthase activity endogenously modulates NMDA receptors. J Neurochem 61:368-370
44. Marras RA, Martins AP, Del Bel EA, Guimarães FS(1995) L-NOARG, an inhibitor of nitric oxide synthase, induces catalepsy in mice. NeuroReport 7:158-160
45. Martin A, Janigian D, Shukitt-Hale B, Prior RL, Joseph JA (1999) Effect of vitamin E intake on levels of vitamins E and C in the central nervous system and peripheral tissues: implications for health recommendations. Brain Res 845:50-59
46. Masserano JM, Gong L, Kulaga H, Baker I, Wyatt RJ (1996) Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol 50:1309-1315
47. Miquel M, Aguilar MA, Aragon CM (1999) Ascorbic acid antagonizes ethanol-induced locomotor activity in the open-field. Pharmacol Biochem Behav 62:361-366
48. Moncada S, Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012
49. Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142
50. Montague PR, Gancayco CD, Winn MJ, Marchase RB, Friedlander MJ (1994) Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science 263:973-977
51. Moore PK, Babbedge RC, Wallace P, Gaffen ZA, Hart SL (1993) 7-Nitroindazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol 108:296-297
52. Morris BJ, Höllt V, Herz A (1988) Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D1 and D2 antagonists. Neuroscience 25:525-532
53. Nucci-da-Silva LP, Guimarães FS, Del Bel EA (1999) Serotonin modulation of catalepsy induced by N(G)-nitro-L-arginine in mice. Eur J Pharmacol 379:47-52
54. Papa SM, Engber TM, Boldry RC, Chase TN (1993) Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur J Pharmacol 232:247-253
55. Pierce RC, Rebec GV (1992) Dopamine-, NMDA- and sigma-receptor antagonists exert differential effects on basal and amphetamine-induced changes in neostriatal ascorbate and DOPAC in awake, behaving rats. Brain Res 579:59-66
56. Pierce RC, Rowlett JK, Rebec GV, Bardo MT (1995) Ascorbate potentiates amphetamine-induced conditioned place preference and forebrain dopamine release in rats. Brain Res 688:21-26
57. Post A, Rucker M, Ohl F, Uhr M, Holsboer F, Almeida OF, Michaelidis TM (2002) Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 26:397-407
58. Rebec GV, Pierce RC (1994) A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. Prog Neurobiol 43:537-565
59. Rebec GV, Wang Z (2001) Behavioral activation in rats requires endogenous ascorbate release in striatum. J Neurosci 21:668-675
60. Reilly DK, Hershey L, Rivera-Calimlim L, Shoulson I (1983) On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy. Adv Neurol 37:51-60
61. Rice ME (2000) Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci 23:209-216
62. Roghani M, Behzadi G (2001) Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res 892:211-217
63. Rondouin G, Bockaert J, Lerner-Natoli M (1993) L-Nitroarginine, an inhibitor of NO synthase, dramatically worsens limbic epilepsy in rats. NeuroReport 4:1187-1190
64. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102:748-759
65. Sandor NT, Brassai A, Puskas A, Lendvai B (1995) Role of nitric oxide in modulating neurotransmitter release from rat striatum. Brain Res Bull 36:483-486
66. Sato K, Saito H, Katsuki H (1993) Synergism of tocopherol and ascorbate on the survival of cultured brain neurones. NeuroReport 4:1179-1182
67. Segieth J, Getting SJ, Biggs CS, Whitton PS (1995) Nitric oxide regulates excitatory amino acid release in a biphasic manner in freely moving rats. Neurosci Lett 200:101-104
68. Seregi A, Schaefer A, Komlos M (1978) Protective role of brain ascorbic acid content against lipid peroxidation. Experientia 34:1056-1057
69. Snyder SH, Bredt DS (1991) Nitric oxide as a neuronal messenger. Trends Pharmacol Sci 12:125-128
70. Snyder SH, Ferris CD (2000) Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 157:1738-1751
71. Spivak B, Schwartz B, Radwan M, Weizman A (1992) Alpha-tocopherol treatment for tardive dyskinesia. J Nerv Ment Dis 180:400-401
72. Starr MS, Starr BS (1995) Do NMDA receptor-mediated changes in motor behaviour involve nitric oxide? Eur J Pharmacol 272:211-217
73. Teagarden MA, Rebec GV (2001) Effects of long-term haloperidol treatment on glutamate-evoked ascorbate release in rat striatum. Eur J Pharmacol 418:213-216
74. Tolbert LC, Thomas TN, Middaugh LD, Zemp JW (1979) Effect of ascorbic acid on neurochemical, behavioral, and physiological systems mediated by catecholamines. Life Sci 25:2189-2195
75. Tolbert LC, Morris PE Jr, Spollen JJ, Ashe SC (1992) Stereospecific effects of ascorbic acid and analogues on D1 and D2 agonist binding. Life Sci 51:921-930
76. Vecsei L, Tajti J, Klivenyi P, Pinter S, Karg E (2001) Sodium azide treatment decreases striatal and cortical concentrations of alpha-tocopherol in rats. J Neural Transm 108:273-278
77. Vincent SR, Kimura H (1992) Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 46:755-784
78. West AR, Galloway MP (1997) Endogenous nitric oxide facilitates striatal dopamine and glutamate efflux in vivo: role of ionotropic glutamate receptor-dependent mechanisms. Neuropharmacology 36:1571-1581
79. Yntema OP, Korf J (1987) Transient suppression by stress of haloperidol induced catalepsy by the activation of the adrenal medulla. Psychopharmacology (Berl) 91:131-134
80. Yoshida Y, Ono T, Kawano K, Miyagishi T (1994) Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. Brain Res 639:139-148
81. Zhu XZ, Luo LG (1992) Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices. J Neurochem 59:932-935